INDEMNITY AGREEMENTIndemnity Agreement • April 18th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement terminates any and all previous indemnification agreements entered into by and between the Company and the Indemnitee.
Ovid Therapeutics Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • April 18th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Ovid Therapeutics Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 18th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Dirk Haasner (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Senior Vice President, Global Regulatory Affairs pursuant to the terms of an Executive Employment Agreement with the Company dated May 16, 2016 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.
